Nonadherence in Outpatient Thrombosis Prophylaxis with Low Molecular Weight Heparins After Major Orthopaedic Surgery

Overview

Journal Clin Orthop Relat Res

Publisher Wolters Kluwer

Specialty Orthopedics

Date 2010 Mar 25

PMID 20333493

Citations 20

Authors

Thomas Wilke

Jorn Moock

Sabrina Muller

Matthias Pfannkuche

Andreas Kurth

Affiliations

Soon will be listed here.

Abstract

Background: According to some current guidelines, extended thromboprophylaxis after hip and knee arthroplasties is recommended. Outpatient prophylaxis with low molecular weight heparins (LMWH) is an important part of this prophylaxis, although the rates of adherence to these regimens is not known.

Questions/purposes: We determined (1) the degree of nonadherence (NA) of patients with LMWH outpatient prophylaxis, and (2) whether specific independent factors explain NA.

Methods: NA was determined by syringe count and by indirect and direct questions to patients. We defined six different NA indicators. To identify factors explaining LMWH NA, we used three different logistic regression models.

Results: NA rates ranged between 13% and 21% depending on the indicator used for measurement. Patients who were nonadherent missed between 38% and 53% of their outpatient LMWH injections. If patients attended an outpatient rehabilitation program, the probability for their NA increased substantially. Moreover, the NA probability increased with each additional day between acute hospitalization and start of rehabilitation (linking days). NA was lower for patients who feared thrombosis or who believed antithrombotic drugs to be the most important measure in thromboprophylaxis.

Level Of Evidence: Level II, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.

Citing Articles

Effectiveness and safety of rivaroxaban or low-molecular-weight heparin in non-major orthopedic surgery: a meta-analysis of randomized controlled trials.

Zhu L, Zhu B, Bing P, Qi M, He B J Orthop Surg Res. 2024; 19(1):609.

PMID: 39342255 PMC: 11438165. DOI: 10.1186/s13018-024-05087-y.

Is It Safe to Resume Direct Oral Anticoagulants upon Discharge after Hip Fracture Surgery? A Retrospective Study.

Katzir A, Fisher-Negev T, Or O, Jammal M, Mosheiff R, Weil Y J Clin Med. 2024; 13(1).

PMID: 38202024 PMC: 10780080. DOI: 10.3390/jcm13010017.

Effectiveness of Thromboprophylaxis Agents Following Hip Fracture: A Systematic Review and Network Meta-Analysis.

Negm A, Yamaura L, Clarke A, Chaudhry D, Cherppukaran T, Schneider P JB JS Open Access. 2023; 8(4).

PMID: 37936980 PMC: 10624462. DOI: 10.2106/JBJS.OA.23.00064.

Inpatient compliance with venous thromboembolism prophylaxis after orthopaedic trauma: results from a randomized controlled trial of aspirin versus low molecular weight heparin.

Haac B, OHara N, Manson T, Slobogean G, Castillo R, OToole R OTA Int. 2021; 4(4):e150.

PMID: 34765900 PMC: 8575420. DOI: 10.1097/OI9.0000000000000150.

Extended thromboprophylaxis for hip or knee arthroplasty. Does the administration route and dosage regimen affect adherence? A cohort study.

Moreno J, Bautista M, Castro J, Bonilla G, Llinas A Int Orthop. 2019; 44(2):237-243.

PMID: 31807853 DOI: 10.1007/s00264-019-04454-3.

References

Eriksson B, Borris L, Friedman R, Haas S, Huisman M, Kakkar A . Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008; 358(26):2765-75. DOI: 10.1056/NEJMoa0800374. View

Colwell Jr C . Thromboprophylaxis in orthopedic surgery. Am J Orthop (Belle Mead NJ). 2006; Suppl:1-9. View

Lassen M, Ageno W, Borris L, Lieberman J, Rosencher N, Bandel T . Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008; 358(26):2776-86. DOI: 10.1056/NEJMoa076016. View

Eriksson B, Dahl O, Buller H, Hettiarachchi R, Rosencher N, Bravo M . A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005; 3(1):103-11. DOI: 10.1111/j.1538-7836.2004.01100.x. View

Stannard J, Lopez-Ben R, Volgas D, Anderson E, Busbee M, Karr D . Prophylaxis against deep-vein thrombosis following trauma: a prospective, randomized comparison of mechanical and pharmacologic prophylaxis. J Bone Joint Surg Am. 2006; 88(2):261-6. DOI: 10.2106/JBJS.D.02932. View

Paes A, Bakker A . Measurement of patient compliance. Pharm World Sci. 1998; 20(2):73-7. DOI: 10.1023/a:1008663215166. View

Petrie K, Weinman J . Why illness perceptions matter. Clin Med (Lond). 2007; 6(6):536-9. PMC: 4952762. DOI: 10.7861/clinmedicine.6-6-536. View

Rolley J, Davidson P, Dennison C, Ong A, Everett B, Salamonson Y . Medication adherence self-report instruments: implications for practice and research. J Cardiovasc Nurs. 2008; 23(6):497-505. DOI: 10.1097/01.JCN.0000338931.96834.16. View

Chisholm M, Lance C, Williamson G, Mulloy L . Development and validation of an immunosuppressant therapy adherence barrier instrument. Nephrol Dial Transplant. 2004; 20(1):181-8. DOI: 10.1093/ndt/gfh576. View

10.

Morisky D, Green L, Levine D . Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24(1):67-74. DOI: 10.1097/00005650-198601000-00007. View

11.

Watts A, Howie C, Simpson A . Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty. J Bone Joint Surg Br. 2005; 88(1):107-10. DOI: 10.1302/0301-620X.88B1.17003. View

12.

Douketis J, Berger P, Dunn A, Jaffer A, Spyropoulos A, Becker R . The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl):299S-339S. DOI: 10.1378/chest.08-0675. View

13.

Liu H, Miller L, Hays R, Golin C, Zhao H, Wenger N . A comprehensive evaluation of survey questions for adherence to antiretroviral medications and exploratory analyses for identifying optimal sets of survey questions. AIDS Patient Care STDS. 2006; 20(11):760-72. DOI: 10.1089/apc.2006.20.760. View

14.

Van Aken H, Bode C, Darius H, Diehm C, Encke A, Gulba D . Anticoagulation: the present and future. Clin Appl Thromb Hemost. 2001; 7(3):195-204. DOI: 10.1177/107602960100700303. View

15.

Colwell Jr C, Pulido P, Hardwick M, Morris B . Patient compliance with outpatient prophylaxis: an observational study. Orthopedics. 2005; 28(2):143-7. DOI: 10.3928/0147-7447-20050201-16. View

16.

Winnick S, Lucas D, Hartman A, Toll D . How do you improve compliance?. Pediatrics. 2005; 115(6):e718-24. DOI: 10.1542/peds.2004-1133. View

17.

Wilke T . Patient preferences for an oral anticoagulant after major orthopedic surgery: results of a german survey. Patient. 2012; 2(1):39-49. DOI: 10.2165/01312067-200902010-00005. View

18.

Eriksson B, Dahl O, Rosencher N, Kurth A, van Dijk C, Frostick S . Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007; 370(9591):949-56. DOI: 10.1016/S0140-6736(07)61445-7. View

19.

Geerts W, Pineo G, Heit J, Bergqvist D, Lassen M, Colwell C . Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 126(3 Suppl):338S-400S. DOI: 10.1378/chest.126.3_suppl.338S. View

20.

Le Gall C, Jacques E, Medjebeur C, Darques L, Briand F, Haddad J . Low molecular weight heparin self-injection training: assessment of feasibility, tolerance and economic analysis in emergency departments. Eur J Emerg Med. 2006; 13(5):264-9. DOI: 10.1097/00063110-200610000-00004. View